Uncategorized

January 7, 2026 Imbria Pharmaceuticals Announces Publication of IMPROVE-DiCE Phase 2a Data in Circulation, Demonstrating Ninerafaxstat as a Potential First-in-Class Therapy Targeting Cardiac Energetics in Cardiometabolic Disease Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart failure with preserved ejection fraction (HFpEF)   In IMPROVE-DiCE, […]

Imbria Pharmaceuticals announced an extension of its Series B financing, now involving AXA IM Alts, to advance ninerafaxstat, a novel therapy for cardiovascular diseases. This funding will support its clinical development amid the global burden of cardiovascular health. New board members, Dr. Zina Affas Besse and Mr. Ken Horne, enhance the company’s expertise.

November 6, 2025 Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy Advances development of ninerafaxstat, a potential first-in-class therapy designed to improve cardiac energetics in patients with serious cardiovascular diseases   Enrollment underway across U.S. sites with U.K. and EU expansion anticipated by end of 2025

March 29, 2025 Imbria Presents Positive Clinical Data from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at ACC.25 Ninerafaxstat improves cardiac energetics, cardiac reserve capacity, 6-minute walk distance and heart failure-related health status (KCCQ) in cardiometabolic HFpEF   Findings support further development of ninerafaxstat in HFpEF and adjacent CV indications such

March 17, 2025 Imbria Pharmaceuticals to Present Results from Phase 2 IMPROVE-DiCE Trial of Ninerafaxstat in Patients with Cardiometabolic HFpEF at the American College of Cardiology Annual Scientific Session & Expo (ACC.25) BOSTON, Mass., March 17, 2025 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and functional

August 30, 2025 Imbria to Present Results from Phase 2 IMPROVE-ISCHEMIA Trial of Ninerafaxstat in Patients with Angina and Chronic Coronary Syndrome at the European Society of Cardiology Congress 2024 Ninerafaxstat was well tolerated and showed no impact on systemic hemodynamics in patients with stable angina and chronic coronary syndrome   These findings support a

April 8, 2024 Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at ACC.24 Improvements in both patient-reported symptoms of heart failure and ventilatory efficiency during exercise testing were demonstrated   Results support initiation of the Phase 3 FORTITUDE-HCM clinical

March 25, 2024 Imbria Pharmaceuticals to Present Results from IMPROVE-HCM Trial of Ninerafaxstat in Late-Breaking Clinical Trial Session at American College of Cardiology Annual Scientific Session & Expo (ACC.24) Ninerafaxstat Phase 2 clinical trial in non-obstructive hypertrophic cardiomyopathy (nHCM) is complete; Phase 3 to be initiated in the 2H 2024   BOSTON, Mass., March 25, 2024 –

November 12, 2023 Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Cardiac Ischemia and Chronic Stable Angina The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety; 8-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement in dobutamine stress-induced ischemic left ventricular (LV) dysfunction compared

November 7, 2023 Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared to placebo, in a robust functional cardiopulmonary exercise test (CPET) measure